A new clinical trial assessing the link between cognitive function and levels of physical activity in patients with Duchenne muscular dystrophy (DMD) is now recruiting participants in Turkey.

The cross-sectional observational study aims to recruit a total of 40 patients with DMD, who are 8 to 14 years of age and are still able to walk. 

The primary outcome measure of the study is the relationship between physical activity levels and the cognitive functions of the participants. The secondary outcome measures are the relationship between balance and body mass index and physical activity levels.


Continue Reading

Read more about the prognosis of muscular dystrophy

Investigators will use the Physical Activity Questionnaire for Children to assess participants’ level of physical activity and the Montreal Cognitive Assessment and the Modified Mini-Mental State Examination to assess their cognitive function. They will use the Pediatric Balance Scale to assess the participants’ balance response and their body mass index to assess their weight status.

Children with a chronic or systemic disease other than DMD, those above level 5 in the Brooke lower extremity functional classification, those who have a cooperation problem, or those who have had any injury or surgery in the arms or legs in the last 6 months are not eligible to take part in the trial.

The study sponsored by Muş Alparlan University and Hacettepe University will take place at Hacettepe University in Ankara, Turkey, and is estimated to be completed by November 1, 2023. 

DMD is characterized by progressive muscle weakness caused by the lack of dystrophin protein due to a mutation in the DMD gene. As the disease progresses, motor function deteriorates until patients are no longer able to walk. As the disease also affects the diaphragm and respiratory muscles, affected people eventually become dependent on a ventilator to breathe. The disease also affects cognitive function in some patients.

Reference

Physical activity level and cognitive functions in children with Duchenne muscular dystrophy. US National Library of Medicine. Updated December 8, 2022. Accessed January 5, 2022.